amifostine anhydrous has been researched along with mesna in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 13 (56.52) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Lewis, C | 1 |
| Raymond, E | 1 |
| Trotti, A | 1 |
| Cao, S; Haridas, K; Hausheer, FH; Kanter, P; Martinez, N; Murali, D; Petluru, P; Reddy, D; Rustum, YM; Saxe, JD; Seetharamulu, P; Yao, S; Zhao, M; Zukowski, A | 1 |
| Lewis, C; Links, M | 1 |
| Broder, G; Cohen, GI; Gradishar, WJ; Green, DM; Hensley, ML; Langdon, RJ; Lindley, C; Meropol, NJ; Mitchell, RB; Negrin, R; Pfister, DG; Schuchter, LM; Szatrowski, TP; Thigpen, JT; Von Hoff, D; Wasserman, TH; Winer, EP | 1 |
| Bernstein, ML; Dubowy, RL; Fahey, RC; Newton, GL; Souid, AK | 1 |
| Bokemeyer, C; Büntzel, J; Wagner, W | 1 |
| Aktas, MK; Bernstein, ML; Dubowy, RL; Fahey, RC; Karjoo, S; Newton, GL; Sadowitz, PD; Sayin, OA; Souid, AK | 1 |
| Boven, E; Erkelens, CA; Hausheer, FH; Hulscher, TM; Pinedo, HM; van der Vijgh, WJ; Verschraagen, M | 1 |
| Hensley, ML; Meropol, NJ; Schuchter, LM; Winer, EP | 1 |
| Grdina, DJ; Kataoka, Y; Murley, JS | 1 |
| Springate, JE; Taub, M; Zaki, EL | 1 |
| Galanski, M; Jakupec, MA; Keppler, BK | 1 |
| Cao, D; Grdina, DJ; Kataoka, Y; Li, JJ; Murley, JS; Oberley, LW | 1 |
| Springate, J; Taub, M | 1 |
| Hogle, WP | 1 |
| Baverel, G; Dubourg, L; Michoudet, C; Yaseen, Z | 1 |
| Cohen, GI; Emami, B; Gradishar, WJ; Green, DM; Hagerty, KL; Hensley, ML; Kewalramani, T; Meropol, NJ; Mitchell, RB; Schuchter, LM; Thigpen, JT; Trotti, A; von Hoff, D; Wasserman, TH | 1 |
| Assa'ad, A; Chow, LM; Davies, SM; Dorris, K; Fouladi, M; Jodele, S; Lawrence, JM; Perentesis, JP; Uygungil, B | 1 |
| Grdina, DJ; Miller, RC; Murley, JS | 1 |
9 review(s) available for amifostine anhydrous and mesna
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review of the use of chemoprotectants in cancer chemotherapy.
Topics: Adrenocorticotropic Hormone; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Humans; Mesna; Neoplasms; Peptide Fragments; Razoxane | 1994 |
[Chemoprotectors. Mechanisms of action and clinical applications].
Topics: Amifostine; Chemoprevention; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Humans; Mesna | 1996 |
Toxicity antagonists in cancer therapy.
Topics: Amifostine; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Growth Substances; Humans; Mesna; Neoplasms; Palliative Care; Radiotherapy; Razoxane; Superoxide Dismutase | 1997 |
Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Interactions; Humans; Kidney Diseases; Mesna; Platinum Compounds; Protective Agents; Sulfhydryl Compounds | 1998 |
Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Topics: Adrenocorticotropic Hormone; Amifostine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Female; Glutathione; Humans; Mesna; Peptide Fragments; Protective Agents; Radiation-Protective Agents; Razoxane | 1999 |
Radioprotectants: current status and new directions.
Topics: Acrolein; Amifostine; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heart; Humans; Mesna; Mutagenesis; Oxazines; Radiation-Protective Agents; Radiotherapy; Razoxane | 2002 |
The effect of cytoprotective agents in platinum anticancer therapy.
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Glutathione; Humans; Mesna; Neoplasms; Platinum Compounds; Protective Agents; Thioctic Acid; Vitamin E | 2004 |
Cytoprotective agents used in the treatment of patients with cancer.
Topics: Amifostine; Antineoplastic Agents; Cytoprotection; Fibroblast Growth Factors; Glutamine; Humans; Mesna; Neoplasms; Razoxane | 2007 |
1 trial(s) available for amifostine anhydrous and mesna
| Article | Year |
|---|---|
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neoplasms; Child; Cyclophosphamide; Cysteine; Female; Humans; Ifosfamide; Infusions, Intravenous; Kinetics; Male; Mesna; Radiation-Protective Agents; Sarcoma, Ewing; Sulfhydryl Compounds; Time Factors | 1999 |
13 other study(ies) available for amifostine anhydrous and mesna
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Topics: Adult; Amifostine; Antineoplastic Agents; Cardiovascular Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 1999 |
[Recommendations of the Working Group 'Supportive Massnahmen in der Onkologie' concerning the Clinical Use of Cytoprotectives].
Topics: Amifostine; Antineoplastic Agents; Cell Survival; Clinical Trials as Topic; Cytoprotection; Humans; Mesna; Neoplasms; Palliative Care; Practice Guidelines as Topic; Radiation-Protective Agents | 2001 |
Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Chromatography, High Pressure Liquid; Disulfides; Female; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Mercaptoethylamines; Mesna; Protective Agents; Radiation-Protective Agents; Sarcoma, Ewing; Sulfhydryl Compounds | 2001 |
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Cell Division; Cisplatin; Drug Interactions; Female; Humans; Lethal Dose 50; Mesna; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Protective Agents; Radiation-Protective Agents; Transplantation, Heterologous; Weight Loss | 2002 |
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Topics: Amifostine; Antineoplastic Agents; Chelating Agents; Humans; Mesna; Neoplasms; Protective Agents; Radiation-Protective Agents; Radiotherapy; Razoxane | 2002 |
Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Antineoplastic Agents; Cells, Cultured; Dose-Response Relationship, Drug; Glucose; Glutathione; Ifosfamide; Kidney Tubules; Mesna; Neutral Red; Rabbits | 2003 |
Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs.
Topics: Acetylcysteine; Amifostine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Captopril; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; I-kappa B Proteins; Mercaptoethylamines; Mesna; Mice; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Plasmids; Protective Agents; Radiation-Protective Agents; Serine; Sulfhydryl Compounds; Superoxide Dismutase; Time Factors; Transfection | 2004 |
Ifosfamide toxicity in cultured proximal renal tubule cells.
Topics: Acetaldehyde; Acrolein; Amifostine; Animals; Cell Culture Techniques; Cells, Cultured; Dose-Response Relationship, Drug; Ifosfamide; Inulin; Ion Transport; Kidney Tubules, Proximal; Male; Mesna; p-Aminohippuric Acid; Protective Agents; Rabbits; Tetraethylammonium | 2007 |
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.
Topics: Acetaldehyde; Acetyl Coenzyme A; Adenosine Triphosphate; Amifostine; Animals; Disease Models, Animal; Drug Therapy, Combination; Glutathione; Glutathione Disulfide; Injections, Intraperitoneal; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Male; Mesna; Organ Culture Techniques; Radiation-Protective Agents; Rats; Rats, Wistar | 2008 |
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Topics: Amifostine; Antineoplastic Agents; Fibroblast Growth Factor 7; Humans; Mesna; Neoplasms; Practice Guidelines as Topic; Radiation-Protective Agents; Razoxane | 2009 |
Severe allergic reactions to thiol-based cytoprotective agents mesna and amifostine in a child with a supratentorial primitive neuroectodermal tumor.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cranial Irradiation; Drug Hypersensitivity; Humans; Male; Mesna; Neuroectodermal Tumors, Primitive; Prognosis; Protective Agents; Sulfhydryl Compounds; Supratentorial Neoplasms | 2011 |
Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs.
Topics: Acetylcysteine; Acute Radiation Syndrome; Amifostine; Animals; Captopril; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Drug Synergism; Endothelial Cells; Fibroblasts; Free Radical Scavengers; Humans; Mesna; Metformin; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Radiation Injuries, Experimental; Radiation-Protective Agents; Sarcoma; Sulfhydryl Compounds | 2014 |